Cat. No.: X23-10-ZQ325
JAK inhibitor JAK/HDAC-IN-1, Purity ≥98%
Synonym: 2284621-75-4; JAK/HDAC-IN-1; 6-(4-((5-Chloro-4-((4-chlorophenyl)amino)pyrimidin-2-yl)amino)-1H-pyrazol-1-yl)-N-hydroxyhexanamide; MUN21754; 6-[4-[[5-Chloro-4-(4-chloroanilino)pyrimidin-2-yl]amino]pyrazol-1-yl]-N-hydroxyhexanamide; JAK inhibitor
- MDL: MFCD32062830
- CAS Number: 2284621-75-4
- Compound CID: 138377596
Product Size
5 mg; 10 mg; 25 mg; 50 mg; 100 mg
Properties
Description
JAK/HDAC-IN-1 is an available JAK small molecule inhibitor with potential antineoplastic activity. It targets HDAC, HDAC2, HDAC6, HDAC8, JAK1, JAK2, JAK3, and Tyk2.
Molecular Formula
C19H21Cl2N7O2
Targets
HDAC: 2 nM; HDAC2: 14 nM; HDAC6: 120 nM; HDAC8: 2470 nM; JAK1: 4.8 nM; JAK2: 4 nM; JAK3: 7.4 nM; Tyk2: 49 nM
Identity
Confirmed by NMR/HPLC/MS.
Applications
JAK/HDAC-IN-1 is researched for its dual inhibition of JAK kinases and HDACs, particularly in hematological malignancies.
Related Products
-
JAK inhibitor 1,2,3,4,5,6-Hexabromocyclohexane, Purity ≥98%
-
JAK inhibitor Abrocitinib, Purity ≥98%
-
JAK inhibitor AZ-3, Purity ≥98%
-
JAK inhibitor AZ-960, Purity ≥98%
-
JAK inhibitor AZD1480, Purity ≥98%
-
JAK inhibitor Baricitinib, Purity ≥98%
Quick Links